Revolutionise Your Oligonucleotide Pipeline to Redefine Therapeutics for CNS Disorders
Building on the sustained success of the US edition over the past five years, 60+ European-based industry leaders will unite in Amsterdam for the inaugural Oligonucleotides for CNS Summit Europe.
Leading experts across neurobiology, oligonucleotide chemistry, PK/PD, in vivo translation and CNS delivery will unite to explore the latest innovations in oligo modifications, conjugation strategies beyond TfR1, next-generation delivery technologies, and translational models designed to tackle previously undruggable neurological targets.
This multidisciplinary forum combines data-driven presentations, interactive roundtables, and networking sessions, providing actionable insights into crossing the BBB, optimising PK/PD, advancing backbone and conjugate design and modifications, and translating preclinical findings into clinical success.
Capitalising on Europe’s growing biotech momentum, this summit offers a unique opportunity to connect with peers from the likes of Roche, Lundbeck and GSK, and discover emerging trends in neurodegeneration, neuromuscular, pain, epilepsy, and rare disease to unlock the full potential of RNA-targeted CNS therapeutics. Position your organisation at the forefront of the rapidly expanding CNS oligonucleotide space with Amsterdam in full tulip season as the backdrop.
What to Expect?
Optimise Oligo Conjugates
Learn strategies for linker–cargo design to maximise therapeutic index while ensuring manufacturability and clinical-grade safety.
Next-Generation CNS Delivery
Explore advanced BBB shuttle technologies and organoid models to enhance CNS penetration.
Translational Insights
Integrate in vitro, PK/PD, and in vivo data to bridge preclinical findings to clinical dosing and efficacy.
Modality & Backbone Innovation
Navigate emerging oligo platforms, safety comparisons, and backbone modifications for safer, more targeted CNS delivery.
Unmissable Event Highlights
Breakfast Briefing
Whether you’re experienced in CNS but new to oligonucleotides, a seasoned oligo scientist exploring CNS, or transitioning from small molecules, bring your team and start the conference on the same page. Gain expert insights and ask your burning questions in an interactive session designed to level-set all attendees.
Networking Opportunities
Connect 1:1 with leading experts, exchange perspectives on the industry’s biggest challenges, and build meaningful relationships through roundtables, open discussions, and dedicated networking hours.
Data-Driven Insights
Hear the latest breakthroughs in CNS-targeted oligonucleotides, including delivery strategies, backbone modifications, translational models, and clinical learnings, all designed to accelerate your research and pipeline.
Explore the Full Event Guide
- 3 days of highly technical, data-driven discussions addressing the challenges unique to CNS development
- Share easily with your team to assess and mobilise interest
- Preview 7+ sessions containing brand-new data at the first European forum dedicated exclusively to CNS-focused oligonucleotide therapeutics
- Hear exclusive content from 16+ expert speakers from GSK, Roche, Contera Pharma, and more
- Unmissable networking opportunities, including roundtable discussions and a poster session
Attending Companies Include
Explore the Agenda
Gain targeted insight into CNS oligonucleotide development, from BBB delivery and conjugation chemistry to translational modelling and clinical learning.
Partner With Us
Position your organisation at the centre of Europe’s CNS oligonucleotide ecosystem as it rapidly scales.
Join Biopharma Experts
Connect with senior CNS, RNA, and oligo leaders shaping the future of RNA-targeted neurological therapies.